Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›

The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›

Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›

Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes. Read More ›

The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources. Read More ›

Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study. Read More ›

Metabolic syndrome is associated with poor prognosis in patients with breast cancer. Identifying potential risk factors for metabolic syndrome may improve outcomes in these women. Read More ›

Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care. Read More ›